- ALYFTREK™ is approved for patients 6 years and older with at least one responsive mutation, including 31 additional mutations not responsive to other CFTR modulator therapies - - In head-to-head ...
Morning Overview on MSN
Gene therapy targets rare cystic fibrosis mutation affecting ~10%
For roughly one in ten people living with cystic fibrosis, the drugs that have transformed survival for most CF patients are ...
The gene editing treatment targets the relatively common 1717-1G>A splicing mutation, which does not respond to many current CF therapies.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug ...
Researchers at the University of Trento have developed a CRISPR-based adenine base editing therapy that repaired the ...
- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene ...
Chronic lung inflammation in cystic fibrosis (CF) often persists even after treatment with newly-approved gene therapies or small molecule CFTR modulators—an unresolved clinical paradox. A new study ...
The FDA approved a once-daily oral combination of vanzacaftor/tezacaftor/deutivacaftor (Alyftrek) for cystic fibrosis (CF) in adults and children 6 years and up ...
- Deutivacaftor/tezacaftor/vanzacaftor approved for people with cystic fibrosis 6 years and older with at least one responsive mutation in the CFTR gene, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results